- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Post-transplant cytomegalovirus (CMV)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 812KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 240KB)
Maribavir – November 2024
Maribavir; Tablet 200 mg; Livtencity®
Last updated
30 May 2025